Corvus Pharmaceuticals, Inc.
Burlingame, California, United States · Biopharma, Biotechnology, Healthcare
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company
Key facts
- Headquarters
- Burlingame, California, United States
- Employees
- Unknown
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (CRVS)
- Website
- corvuspharma.com
Recent activity at Corvus Pharmaceuticals, Inc.
- : SEC 8-K (8.01): On January 20, 2026, Corvus Pharmaceuticals, Inc. announced the suspension of its proposed registered underwritten public offering of common stock. This decision was communicated to Jefferies LLC, the underwriter, and relates to a previous Sale Agreement established on August 6, 2024, which permitted the sale of up to $100 million of common stock under a shelf registration statement. Prior to this suspension, no shares had been sold under the agreement, and all $100 million worth of shares remained available for future transactions. The strategic implications of this suspension indicate a potential adjustment in the company's capital raising strategy.
- : Corvus Pharmaceuticals Publishes Preclinical Data on Soquelitinib for Tumor Immunity Modulation
- : Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer
- : Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2015 | Venture | $75.0M |
Leadership
- Jeffrey Arcara, Chief Business Officer
Verified email and direct lines for Corvus Pharmaceuticals, Inc.’s decision-makers are on Fundz. See plans
Corvus Pharmaceuticals, Inc. in the news
- Corvus Pharmaceuticals Announces Initiation of Phase 1b - GlobeNewswire (Sep 30, 2026)
- Corvus Pharmaceuticals’ Soquelitinib Shows Rapid, Dose-Dependent Efficacy in Phase 1 AD Trial - Dermatology Times (May 08, 2025)
- Drug-free remissions seen after short atopic dermatitis treatment - Stock Titan (May 14, 2026)
- Novel TK1 Inhibitor Demonstrates Rapid, Dose-Dependent Efficacy in Atopic Dermatitis in Ph 1 Trial - Patient Care Online (May 12, 2025)
- Soquelitinib Phase 1 Data Show Sustained Clinical Improvement With Extended Treatment in AD - Dermatology Times (Jan 20, 2026)
- FDA Grants Fast Track Designation to Soquelitinib for Relapsed/Refractory PTCL - OncLive (Aug 01, 2024)
- One drug is now in trials for four conditions, including a skin disease. - Stock Titan (Sep 30, 2026)
- Corvus Pharmaceuticals (CRVS) Stock Price, News & Analysis $CRVS - MarketBeat (Aug 15, 2016)
Companies similar to Corvus Pharmaceuticals, Inc.
- AbbVie Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Savara Inc · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- ISOThrive · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Mereo Biopharma Group plc · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Milestone Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
About Corvus Pharmaceuticals, Inc.: questions and answers
What does Corvus Pharmaceuticals, Inc. do?
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company
Where is Corvus Pharmaceuticals, Inc. headquartered?
Corvus Pharmaceuticals, Inc. is headquartered in Burlingame, California, United States.
Has Corvus Pharmaceuticals, Inc. raised funding?
Yes. Fundz has recorded 1 funding event for Corvus Pharmaceuticals, Inc.. The most recent, $75.0M, was in Sep 2015.
What is the latest news on Corvus Pharmaceuticals, Inc.?
On Jan 20, 2026, SEC 8-K (8.01): On January 20, 2026, Corvus Pharmaceuticals, Inc. announced the suspension of its proposed registered underwritten public offering of common stock. This decision was communicated to Jefferies LLC, the underwriter, and relates to a previous Sale Agreement established on August 6, 2024
Is Corvus Pharmaceuticals, Inc. a public company?
Yes. Corvus Pharmaceuticals, Inc. is publicly traded under the ticker CRVS.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy